A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations

Trial Profile

A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2018

At a glance

  • Drugs Olaparib (Primary) ; Capecitabine; Eribulin; Vinorelbine
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OlympiAD
  • Sponsors AstraZeneca
  • Most Recent Events

    • 02 Jul 2018 According to an AstraZeneca media release, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved Lynparza (olaparib) tablets for use in patients with unresectable or recurrent BRCA-mutated, HER2 negative breast cancer who have received prior chemotherapy. The approval is based on data from this trial.
    • 05 Jun 2018 Results assessing the impact of treatment on symptoms using the QLQ-C30 questionnaire, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results assessing efficacy of olaparib versus treatment of physicians choice in mBC patients with specific sites of visceral metastasis presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top